TheScreener - Dechra Pharmaceuticals PLC (DPH) DECHRA PHARMACEUTICALS sees an upgrade to Slightly Positive due to a better fundamental star rating

Report

TheScreener

EUR 12.94 For Business Accounts Only

DECHRA PHARMACEUTICALS sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of DECHRA PHARMACEUTICALS (GB), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 1 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date December 31, 2021, the closing price was GBp 5,325.00 and its potential was estimated at GBp 5,655.81.

01/01/2022 6 EN

Underlying

Dechra Pharmaceuticals PLC

Dechra Pharmaceuticals is engaged in the veterinary pharmaceuticals and related products business. Co. has three reportable segments: European Pharmaceuticals, manufactures and markets Companion Animal, Equine and Food producing Animal Products and also includes third party manufacturing; North American Pharmaceuticals, which consists of Dechra Veterinary Products US, Putney, Dechra Veterinary Products Canada, and Dechra-Brovel, which sells Companion Animal, Equine Products and Food producing Animal Products in those territories; and Pharmaceuticals Research and Development, which includes all of Co.'s pharmaceutical research and development activities.

See profile

GB0009633180 London Stock Exchange United Kingdom

Provider

TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.

See profile

Other Reports on these Companies

EQS Group AG

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc 15-Jan-2024 / 13:46 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the t...

January 15, 2024 January 15, 2024 1 EN

EQS Group AG

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc 12-Jan-2024 / 13:37 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the t...

January 12, 2024 January 12, 2024 1 EN

EQS Group AG

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc 11-Jan-2024 / 14:15 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the t...

January 11, 2024 January 11, 2024 1 EN

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

AC ENERGY CORP (PH), a company active in the Alternative Electricity industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 4 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date April 8, 2022, the closing price was PHP 8.54 and its expected value was estimated at PHP 8.53.

Free Trial

April 9, 2022 April 9, 2022 1 EN

With a more favourable environment, VUKILE PROPERTY improves to Positive

VUKILE PROPERTY (ZA), a company active in the Real Estate Holding & Development industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date April 5, 2022, the closing price was ZAR 13.72 and its potential was estimated at ZAR 15.16.

Free Trial

April 6, 2022 April 6, 2022 1 EN

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of ROYAL BAFOKENG PLATINUM (ZA), active in the Platinum & Precious Metals industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date April 5, 2022, the closing price was ZAR 159.78 and its target price was estimated at ZAR 127.50.

Free Trial

April 6, 2022 April 6, 2022 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

DECHRA PHARMACEUTICALS sees an upgrade to Slightly Positive due to a better fundamental star rating

Empowering Investors

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

With a more favourable environment, VUKILE PROPERTY improves to Positive

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe